Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch — are investors ready to forgive Axovant?
Love him or hate him, and there are plenty of people in both camps now, Vivek Ramaswamy is never boring.
On Friday Ramaswamy’s Dermavant — part of the growing Roivant camp he runs — inked a $330 million deal to gain the worldwide rights to a Phase III-ready psoriasis drug from GlaxoSmithKline. That was two days after Ramaswamy recruited Genentech vet Myrtle Potter to come in as a Roivant operating chair for the group of biotechs he has ramped up. He also launched his 12th company — Immunovant — just days after reorganizing the company, which now collectively has more than 600 staffers.
And here’s something new: He capped the week by handing over an S-1 for Urovant, his urology company in search of a $150 million-plus IPO to cover the cost of their Phase III program.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
